Anika Therapeutics' (NASDAQ:ANIK) stock falls as the company's cartilage repair product Hyalofast misses key trial endpoints ...

Shares of Anika Therapeutics hit a 52-week low after it said its Hyalofast cartilage-repair product didn't meet its co-primary endpoints in a Phase III study. The stock was recently down 24% to $8.43 ...

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the ...

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

OvertureTi Knee Resurfacing System implants are designed specifically as an alternative when biological repair options are not viable for treating focal cartilage lesions.

The ankle's ability to regenerate cartilage uses the same mechanisms that enable some animals to grow new limbs, and it could be harnessed to repair cartilage in knees and hips hobbled by ...

Recently, a research team from Chongqing Medical University, led by Prof. Wei Huang, Dr. Wei Bao, and Dr. Yiting Lei, has successfully developed a novel engineered extracellular matrix (eECM) to ...